| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL-12 andIL-23 |
| Clinical data | |
| Trade names | Stelara |
| Other names | CNTO 1275 |
| Biosimilars | ustekinumab-aauz,[1] ustekinumab-aekn,[2] ustekinumab-auub,[3] ustekinumab-kfce,[4] ustekinumab-srlf,[5] ustekinumab-stba,[6] ustekinumab-ttwe,[7] Absimky,[8][9] Eksunbi,[10][11] Fymskina,[12][13] Imuldosa,[5] Jamteki,[14] Otulfi,[1][15][16] Pyzchiva,[7][17][18] Selarsdi,[2] Steqeyma,[6][19][20] Uzpruvo,[21] Wezlana,[3][22] Wezenla,[23][24] Yesintek[4] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611013 |
| License data | |
| Pregnancy category | |
| Routes of administration | Subcutaneous,intravenous |
| Drug class | Immunosuppressant interleukin inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | unknown[28] |
| Eliminationhalf-life | 15–32 days (average 3 weeks)[28] |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6482H10004N1712O2016S46 |
| Molar mass | 145648.06 g·mol−1 |
 N Y (what is this?) (verify) | |
Ustekinumab, sold under the brand nameStelara among others, is amonoclonal antibody medication used for the treatment ofCrohn's disease,ulcerative colitis,plaque psoriasis andpsoriatic arthritis,[31] targeting both IL-12 and IL-23.[32] It is administered either byintravenous infusion orsubcutaneous injection.[31] The antibody targets a subunit of humaninterleukin 12 andinterleukin 23, which are naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.[33] Ustekinumab is a fully human IgG1κ monoclonal antibody that binds to the p40 subunit of interleukin 12 and 23, thereby preventing them from binding to the IL 12Rβ1 receptor expressed on the surface of immune cells.[34] By doing so, ustekinumab prevents the activation of the Th1 and Th17 cytokine pathways, which are central to the pathology of plaque psoriasis, psoriatic arthritis and Crohn's disease.[34] Ustekinumab was developed by Centocor Ortho Biotech.[35]
Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union; and ulcerative colitis in the United States, and in the European Union to people who have not responded to more traditional treatments.[29][30][36][37] It was found not effective formultiple sclerosis.[38]
Ustekinumab is used to treatpsoriasis.[29] This includespsoriatic arthritis when it affects the skin.[31][29] It is indicated for the treatment of adult and adolescent patients (12 years and older) with moderate to severeplaque psoriasis (Ps) who are candidates forphototherapy or systemic therapy, and adults with active psoriatic arthritis (PsA) alone or in combination withmethotrexate.[29][39] It is also used to treat moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis.[29]
In the European Union, ustekinumab is authorized for the treatment of moderate to severe plaque psoriasis in people above the age of six years whose condition has not improved with, or who cannot use, other systemic (whole-body) psoriasis treatments, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A);[30] active psoriatic arthritis in adults;[30] moderately to severely active Crohn's disease in adults;[30] and moderately to severely active ulcerative colitis in adults.[30]
The most common side effects includeupper respiratory tract infection,headache,fatigue,nausea,vomiting, nasopharyngitis, injection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis, pruritus,urinary tract infection, sinusitis, abdominal pain, fever, and diarrhea.[29] Clinical trials have shown that subcutaneous ustekinumab was generally well tolerated. Most treatment-emergent adverse events were of mild severity.[40]
It is unknown if the medication is safe during pregnancy or breastfeeding.[28]
Ustekinumab is designed to interfere with the triggering of the body'sinflammatory response through the suppression of certaincytokines. Specifically, it blocksinterleukinIL-12 andIL-23 which help activate certainT-cells. It binds to thep-40 subunit of both IL-12 and IL-23 so that they subsequently cannot bind to their receptors.[41]
In December 2007, abiologic license application with the USFood and Drug Administration (FDA) was filed by Centocor;[35][42] andJanssen-Cilag International (collaborator) submitted a marketing authorization application to theEuropean Medicines Agency (EMA). In November 2008, theCommittee for Medicinal Products for Human Use of the EMA adopted a positive opinion for ustekinumab for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to other systemic therapies.[30]
Ustekinumab is approved in Canada, the European Union, and the United States to treat moderate to severeplaque psoriasis.[43] In September 2013, the USFood and Drug Administration (FDA) approved the use of ustekinumab for the treatment ofpsoriatic arthritis.[44]
In December 2008,Health Canada approved the use of ustekinumab for the treatment of chronic moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy.[45][46]
The FDA approved ustekinumab in September 2009, for the treatment of adults with moderate to severe plaque psoriasis.[47][35]
The FDA approved ustekinumab in September 2016, to treat Crohn's disease.[48]
Since September 2017, ustekinumab has been available on the AU Pharmaceutical Benefits Scheme to treat severe Crohn's disease in adults.[49]
In 2019, the European Commission authorized the use of ustekinumab for adults with moderately to severely active ulcerative colitis.[36][30]
In October 2019, the FDA approved the use of ustekinumab for adults with moderately to severely active ulcerative colitis.[50][51]
In October 2023, ustekinumab-auub (Wezlana) was approved for medical use in the United States.[3][52]
In November 2023, theCommittee for Medicinal Products for Human Use (CHMP) of theEuropean Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Uzpruvo, intended for the treatment of plaque psoriasis, including pediatric plaque psoriasis,[53] psoriatic arthritis and Crohn's disease in adults.[53] The applicant for this medicinal product is STADA Arzneimittel AG.[53] Uzpruvo is a biosimilar medicinal product.[53] Uzpruvo was authorized for medical use in the European Union in January 2024.[21][54]
In November 2023, Jamteki was approved for medical use in Canada.[14][55][56]
In December 2023, Wezlana and Wezlana I.V. were approved for medical use in Canada.[57][58]
In February 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Pyzchiva, intended for the treatment of plaque psoriasis, including pediatric plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn's disease in adults.[17] The applicant for this medicinal product is Samsung Bioepis NL B.V.[17] Pyzchiva is a biosimilar medicinal product.[17] Pyzchiva was authorized for medical use in the European Union in April 2024.[17][18]
Ustekinumab-aekn (Selarsdi) was approved for medical use in the United States in April 2024.[2][52]
In April 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Wezenla, intended for the treatment of plaque psoriasis, including pediatric plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults.[23][59] The applicant for this medicinal product is Amgen Technology (Ireland) UC.[23] Wezenla was authorized for medical use in the European Union in June 2024.[23][24]
Ustekinumab-ttwe (Pyzchiva) was approved for medical use in the United States in June 2024.[7][52]
In June 2024, the CHMP recommended granting a marketing authorization for Steqeyma, a biosimilar medicine for the treatment of adults with moderately-to severely-active Crohn's disease, plaque psoriasis, pediatric plaque psoriasis and psoriatic arthritis.[19][60] The applicant for this medicinal product is Celltrion Healthcare Hungary Kft.[19] Steqeyma was authorized for medical use in the European Union in August 2024.[19][20]
In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Eksunbi, intended for the treatment of plaque psoriasis, including pediatric plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn's disease in adults.[10] The applicant for this medicinal product is Samsung Bioepis NL B.V.[10] Eksunbi is a biosimilar medicinal product.[10] Eksunbi is a biosimilar medicinal product.[10] Eksunbi was authorized for medical use in the European Union in September 2024.[10][11]
In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Otulfi, intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease.[15] The applicant for this medicinal product is Fresenius Kabi Deutschland GmbH.[15] Otulfi is a biosimilar medicinal product.[15] Otulfi was authorized for medical use in the European Union in September 2024.[15][16]
In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Fymskina, intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis, ulcerative colitis or Crohn's disease.[12] The applicant for this medicinal product is Formycon AG.[12] Fymskina is a biosimilar medicinal product.[12] Fymskina was authorized for medical use in the European Union in September 2024.[12][13]
In July 2024, Steqeyma and Steqeyma IV were approved for medical use in Canada.[61]
In August 2024, Pyzchiva and Pyzchiva I.V. were approved for medical use in Canada.[62][63]
Steqeyma was approved for medical use in Australia in September 2024.[64]
In September 2024, ustekinumab-aauz (Otulfi) was approved for medical use in the United States.[1][65][52]
Ustekinumab-srlf (Imuldosa) was approved for medical use in the United States in October 2024.[5][66][52]
In October 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Absimky, intended for the treatment of people with plaque psoriasis and adults with psoriatic arthritis, Crohn's disease, or ulcerative colitis.[8] The applicant for this medicinal product is Accord Healthcare S.L.U.[8] Absimky is a biosimilar medicinal product.[8][67] Absimky was authorized for medical use in the European Union in December 2024.[9]
In October 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Imuldosa, intended for the treatment of people with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease.[68] The applicant for this medicinal product is Accord Healthcare S.L.U.[68] Imuldosa is a biosimilar medicinal product.[68] Imuldosa was authorized for medical use in the European Union in December 2024.[69]
Ustekinumab-kfce (Yesintek) was approved for medical use in the United States in December 2024.[4][52]
In December 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Yesintek, intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease.[34] The applicant for this medicinal product is Biosimilar Collaborations Ireland Limited.[34] Yesintek is a biosimilar medicinal product.[34] It is highly similar to the reference product Stelara (ustekinumab), which was authorized in the EU in January 2009.[34]
Ustekinumab-stba (Steqeyma) was approved for medical use in the United States in December 2024.[6][52]
This article incorporates text from this source, which is in thepublic domain.{{cite web}}: CS1 maint: archived copy as title (link)
